N/A
Manufactured by Amneal Pharmaceuticals LLC
48,940 FDA adverse event reports analyzed
Last updated: 2026-04-14
MOMETASONE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Amneal Pharmaceuticals LLC. The most commonly reported adverse reactions for MOMETASONE include DYSPNOEA, ASTHMA, DRUG INEFFECTIVE, HEADACHE, COUGH. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for MOMETASONE.
Out of 17,178 classified reports for MOMETASONE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 48,940 FDA FAERS reports that mention MOMETASONE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DYSPNOEA, ASTHMA, DRUG INEFFECTIVE, HEADACHE, COUGH, FATIGUE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Amneal Pharmaceuticals LLC in connection with MOMETASONE. Always verify the specific product and NDC with your pharmacist.